Clinical Trials Browser

Neoplasm Metastasis × trastuzumab deruxtecan × 90 days × Clear all

NCT05372614 2026-04-14

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase 1 Suspended

33 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04585958 2026-04-13

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Phase 1 Recruiting

55 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04704661 2026-04-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Phase 1 Recruiting

51 enrolled

BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06311214 2026-04-13

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase 2 Recruiting

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06364410 2026-04-13

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Phase 1 Recruiting

48 enrolled

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT06663787 2026-04-13

HER2 CR

Active not recruiting

50 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT07137416 2026-04-13

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Recruiting

36 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04639219 2026-03-23

DPT01

Phase 2 Active not recruiting

102 enrolled 18 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT07454668 2026-03-06

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Phase 1 Not yet recruiting

20 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04294628 2026-02-27

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Phase 1 Active not recruiting

62 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06058988 2026-02-23

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Phase 2 Recruiting

30 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT04784715 2026-02-20

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase 3 Active not recruiting

1,157 enrolled 2 FDA

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT07407465 2026-02-17

CHIMERA

Phase 2 Recruiting

42 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms